Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy

Diabetologia

Volumn 56, Issue 9, 2013, Pages 1934-1943

  Wheeler, S ^a   Moore, K ^a   Forsberg, C W ^a   Riley, K ^a   Floyd, J S ^b   Smith, N L ^a,b,c   Boyko, E J ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Cohort study; Diabetes mellitus; Monotherapy; Mortality; Oral hypoglycaemic medication; Pharmacoepidemiology; Veterans

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION; UNITED STATES; VETERAN; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME;

DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS; UNITED STATES; VETERANS;

EID: 84881567755     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2958-1     Document Type: Article

References (42)

1. CDC (2012) Age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997-2010. Available from www.cdc.gov/diabetes/statistics/meduse/fig2.htm. Accessed 20 July 2012
2. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P (2012) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 156:218-231
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
4. Chien HH, Chang CT, Chu NF et al (2007) Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc 70:473-480
5. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541-549
6. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS (2003) Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 88:3598-3604
7. Goldstein BJ, Pans M, Rubin CJ (2003) Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 25:890-903
8. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
9. Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(Suppl):789-830
10. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471
11. Kaul S, Diamond GA (2011) Is there clear and convincing evidence of cardiovascular risk with rosiglitazone? Clin Pharmacol Ther 89:773-776
12. Winterstein AG (2011) Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Ther 89:776-778
13. Loke YK, Kwok CS, Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342:d1309
14. Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191-1201
15. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-1195
16. Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S (2010) Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 19:335-342
17. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345-2351
18. Evans JM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936
19. Gulliford M, Latinovic R (2004) Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239-245
20. Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248
21. Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900-1908
22. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA (2006) Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174:169-174
23. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915-920
24. (2009) Selected Veterans Health Administration Characteristics: FY2002 to FY2011. Available from www.va.gov/vetdata/Utilization.asp. Accessed 20 Aug 2012
25. Cowper DC, Kubal JD, Maynard C, Hynes DM (2002) A primer and comparative review of major US mortality databases. Ann Epidemiol 12:462-468
26. Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3-15
27. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389-394
28. Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus, a cohort study. Ann Intern Med 157:601-610
29. Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731
30. Kahler KH, Rajan M, Rhoads GG et al (2007) Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 30:1689-1693
31. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135
32. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411-418
33. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942
34. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634-2643
35. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299-304
36. Stevens RJ, Ali R, Bankhead CR et al (2012) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:2593-2603
37. Walker AM (1996) Confounding by indication. Epidemiology 7:335-336
38. Cummings P (2008) Propensity scores. Arch Pediatr Adolesc Med 162:734-737
39. Shah BR, Laupacis A, Hux JE, Austin PC (2005) Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58:550-559
40. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59:437-447
41. Brown DW (2010) Smoking prevalence among US veterans. J Gen Intern Med 25:147-149
42. Psaty BM, Weiss NS, Furberg CD et al (1999) Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786-790